A low molecular weight PSMA-based fluorescent imaging agent for cancer

Chen, Ying; Dhara, Surajit; Banerjee, Sangeeta Ray; Byun, Youngjoo; Pullambhatla, Mrudula; Mease, Ronnie C.; Pomper, Martin G.

doi:10.1016/j.bbrc.2009.10.017

Cited by 121 publications

(149 citation statements)

References 31 publications

Supporting

Mentioning

146

Contrasting

Order By: Relevance

“…NIRF imaging is a sensitive technique that may be exploited to improve visualization of small to microscopic malignant lesions and potentially of positive resection margins during surgery. So far, several preclinical studies have evaluated methods to intraoperatively visualize tumor tissue and resection margins in prostate cancer (12)(13)(14). Targeted approaches using antibodies or peptides are particularly promising to apply dual-modality imaging.…”

Section: Discussionmentioning

confidence: 99%

Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer

et al. 2014

View full text Add to dashboard Cite

Radical removal of malignant lesions may be improved using tumor-targeted dual-modality probes that contain both a radiotracer and a fluorescent label to allow for enhanced intraoperative delineation of tumor resection margins. Because pretargeting strategies yield high signal-to-background ratios, we evaluated the feasibility of a pretargeting strategy for intraoperative imaging in prostate cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12) in conjunction with the dual-labeled diHSG peptide (RDC018) equipped with both a DOTA chelate for radiolabeling purposes and a fluorophore (IRdye800CW) to allow near-infrared optical imaging. Nude mice implanted s.c. with TROP-2-expressing PC3 human prostate tumor cells or with PC3 metastases in the scapular and suprarenal region were injected i.v. with 1 mg of TF12 and, after 16 hours of tumor accumulation and blood clearance, were subsequently injected with 10 MBq, 0.2 nmol/mouse of either 111 In-RDC018 or 111 In-IMP288 as a control. Two hours after injection, both microSPECT/CT and fluorescence images were acquired, both before and after resection of the tumor nodules. After image acquisition, the biodistribution of 111 In-RDC018 and 111 In-IMP288 was determined and tumors were analyzed immunohistochemically. The biodistribution of the dual-label RDC018 showed specific accumulation in the TROP-2-expressing PC3 tumors (12.4 AE 3.7% ID/g at 2 hours postinjection), comparable with 111 In-IMP288 (9.1 AE 2.8% ID/g at 2 hours postinjection). MicroSPECT/CT and near-infrared fluorescence (NIRF) imaging confirmed this TROP-2-specific uptake of the dual-label 111 In-RDC018 in both the s.c. and metastatic growing tumor model. In addition, PC3 metastases could be visualized preoperatively with SPECT/CT and could subsequently be resected by imageguided surgery using intraoperative NIRF imaging, showing the preclinical feasibility of pretargeted dualmodality imaging approach in prostate cancer. Cancer Res; 74(21); 6216-23. Ó2014 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It has a PSMA inhibitory activity of 0.37 nM, which is capable of generating target-to-nontarget ratios of at least 10 fold in PSMA-expressing PC3-PIP vs PSMA-negative PC3-flu tumors in vivo. It is useful for the study of PSMA-expressing tissue in preclinical models or for intraoperative guidance [38]. …”

Section: Imaging Probes For Prostate Cancer Based On Psmamentioning

confidence: 99%

Recent Development and Trends in Molecular Imaging Probes for Prostate Cancer

Zeng¹,

Liu²,

Wang³

2012

Molecular Imaging

View full text Add to dashboard Cite

“…Molecular imaging agents have been designed for MR, 89-91 nuclear, 92,93 optical, 94,95 computed tomography 96 and ultrasound imaging. 97,98 The agents are classically designed as activatable or targeted agents.…”

Section: Molecular Imagingmentioning

confidence: 99%

The role of imaging and molecular imaging in the early detection of metabolic and cardiovascular dysfunctions

et al. 2010

View full text Add to dashboard Cite

Despite intense effort, obesity is still rising throughout the world. Links between obesity and cardiovascular diseases are now well established. Most of the cardiovascular changes related to obesity can be followed by magnetic resonance imaging (MRI) or by magnetic resonance spectroscopy (MRS). In particular, we will see in this review that MRI/MRS is extremely well suited to depict (1) changes in cardiac mass and function, (2) changes in stroke volume, (3) accumulation of fat inside the mediastinum or even inside the cardiomyocytes, (4) cell viability and (5) molecular changes during early cardiovascular diseases.

show abstract

A low molecular weight PSMA-based fluorescent imaging agent for cancer

Cited by 121 publications

References 31 publications

Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer

Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer

Recent Development and Trends in Molecular Imaging Probes for Prostate Cancer

The role of imaging and molecular imaging in the early detection of metabolic and cardiovascular dysfunctions

Contact Info

Product

Resources

About